Oberweis Asset Management Inc. purchased a new stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 466,600 shares of the company's stock, valued at approximately $6,122,000. Oberweis Asset Management Inc. owned about 0.54% of Pediatrix Medical Group as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MD. Pacer Advisors Inc. bought a new position in shares of Pediatrix Medical Group during the fourth quarter valued at about $35,492,000. American Century Companies Inc. grew its position in shares of Pediatrix Medical Group by 628.2% in the 4th quarter. American Century Companies Inc. now owns 1,739,323 shares of the company's stock worth $22,820,000 after buying an additional 1,500,485 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Pediatrix Medical Group by 117.4% during the fourth quarter. Renaissance Technologies LLC now owns 838,800 shares of the company's stock valued at $11,005,000 after buying an additional 453,000 shares during the period. Boston Partners raised its holdings in shares of Pediatrix Medical Group by 25.2% during the fourth quarter. Boston Partners now owns 1,956,353 shares of the company's stock valued at $25,922,000 after acquiring an additional 393,600 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Pediatrix Medical Group in the fourth quarter worth $3,066,000. 97.71% of the stock is currently owned by institutional investors.
Pediatrix Medical Group Stock Up 0.2 %
Shares of MD traded up $0.02 during mid-day trading on Wednesday, reaching $12.58. The company had a trading volume of 114,171 shares, compared to its average volume of 837,645. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $17.67. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.42 and a current ratio of 1.60. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -10.48, a price-to-earnings-growth ratio of 1.74 and a beta of 1.32. The firm has a 50-day moving average price of $13.91 and a 200 day moving average price of $13.98.
Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.12. The firm had revenue of $502.36 million during the quarter, compared to the consensus estimate of $486.22 million. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. On average, sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.
Analysts Set New Price Targets
Several research analysts have commented on MD shares. StockNews.com upgraded shares of Pediatrix Medical Group from a "hold" rating to a "buy" rating in a report on Wednesday, January 22nd. Truist Financial lowered their price objective on shares of Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating for the company in a report on Friday, April 11th. Finally, UBS Group upped their target price on Pediatrix Medical Group from $16.50 to $18.50 and gave the stock a "neutral" rating in a report on Friday, February 21st. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $16.75.
Read Our Latest Stock Analysis on MD
Pediatrix Medical Group Profile
(
Free Report)
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Read More

Before you consider Pediatrix Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.
While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.